Asset profile
Talazoparib
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: HR+/HER2- Metastatic Breast Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Talazoparib: this drug | Approved | Small molecule | PARP | ||
| Olaparib | Approved | Small molecule | PARP | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Docetaxel | Approved | Small molecule | Microtubules (tubulin) | ||
| Elacestrant | Approved | Small molecule | Estrogen receptor | ||
| Eribulin Mesylate | Approved | Small molecule | Tubulin / microtubules | ||
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | ||
| Exemestane | Approved | Small molecule | Aromatase | ||
| Fulvestrant (Faslodex) | Approved | Small molecule | Estrogen receptor | ||
| Gedatolisib | Approved | Small molecule | PI3K (class I isoforms) and mTORC1/mTORC2 |
…and 46 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(25 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (5)
December 2026 (5)
Phase 1/2Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor …Recruiting
Est. primary completion 2026-12-31 · NCT04901702 · CT.gov ↗
What to watch
Phase 2Prostate CancerRecruiting
Est. primary completion 2026-12-31 · NCT05873192 · CT.gov ↗
What to watch
Phase 2Advanced Malignant Neoplasm, ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Metastatic Malignant Neoplasm …Active not recruiting
Est. primary completion 2026-12-31 · NCT02286687 · CT.gov ↗
What to watch
Phase 2Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid NeoplasmActive not recruiting
Est. primary completion 2026-12-31 · NCT05327010 · CT.gov ↗
What to watch
Phase 3Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid TumorsActive not recruiting
Est. primary completion 2026-12-31 · NCT05059522 · CT.gov ↗
What to watch
2027 (12)
January 2027 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-01 · NCT04039230 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03-31 · NCT03990896 · CT.gov ↗
What to watch
April 2027 (2)
May 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-05-31 · NCT04892693 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 …Recruiting
Est. primary completion 2027-08-23 · NCT04734730 · CT.gov ↗
What to watch
September 2027 (2)
October 2027 (1)
Phase 1Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma …Recruiting
Est. primary completion 2027-10-01 · NCT03968406 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1/2Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers, Metastatic Triple Negative Breast CancersRecruiting
Est. primary completion 2027-11 · NCT05035745 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid NeoplasmRecruiting
Est. primary completion 2027-12-31 · NCT04693468 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
2028 (2)
June 2028 (1)
Phase 1/2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-06 · NCT05319249 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma …Recruiting
Est. primary completion 2028-09-01 · NCT04511039 · CT.gov ↗
What to watch
2029 (3)
March 2029 (1)
Phase 2Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)Recruiting
Est. primary completion 2029-03 · NCT06844383 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1Neuroendocrine TumorsRecruiting
Est. primary completion 2029-06-30 · NCT05053854 · CT.gov ↗
What to watch
August 2029 (1)
Phase 1Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Chronic Myelomonocytic Leukemia …Recruiting
Est. primary completion 2029-08-22 · NCT06218628 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
2033 (1)
November 2033 (1)
Phase 2Ovarian Cancer, Peritoneal Cancer, Fallopian Tube CancerRecruiting
Est. primary completion 2033-11-30 · NCT05071937 · CT.gov ↗
What to watch
2038 (1)
December 2038 (1)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2038-12-31 · NCT05725200 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.